THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [4.14] ID: TIP-MED-000058 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Insulin Glargine (U-100 & U-300)

Active Ingredient / Scientific Identity: Insulin Glargine • Class: Long-Acting (Basal) Recombinant Human Insulin Analogue (Peakless 24-Hour Basal Profile)

⚖️ Compare Profile
Generic / Entity NameInsulin Glargine (U-100 & U-300) ([4.14])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassLong-Acting (Basal) Recombinant Human Insulin Analogue (Peakless 24-Hour Basal Profile)
Available Dosage FormsPrefilled Disposable Pens (SoloStar / KwikPen, 3 mL), Cartridges (3 mL), and Vials (10 mL): 100 IU/mL (U-100);
Regulatory ClassificationSchedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this pre
Key Warning & Review DateRenal: Dosing depends on renal clearance! Reduce glargine dose by 20–35% as eGFR declines below 45 and 30 mL/min. Hepatic: Re
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H & Schedule G Prescription Drug ('Caution:🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Insulin Glargine (U-100 & U-300) (TIP-MED-000058, Reference Code [4.14]) is classified under Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Long-Acting (Basal) Recombinant Human Insulin Analogue (Peakless 24-Hour Basal Profile). Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.14], p. 51): U-100 (100 IU/mL): Lantus (Sanofi), Basalog (Biocon), Glaritus (Wockhardt), Basaglar (Lilly); U-300 Concentrated (300 IU/mL): Toujeo (Sanofi) — Strengths & Dosage Forms: Prefilled Disposable Pens (SoloStar / KwikPen, 3 mL), Cartridges (3 mL), and Vials (10 mL): 100 IU/mL (U-100); Concentrated Prefilled Pen (Toujeo): 300 IU/mL (U-300)
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.14], p. 51): U-100 (100 IU/mL): Lantus (Sanofi), Basalog (Biocon), Glaritus (Wockhardt), Basaglar (Lilly); U-300 Concentrated (300 IU/mL): Toujeo (Sanofi) — Strengths & Dosage Forms: Prefilled Disposable Pens (SoloStar / KwikPen, 3 mL), Cartridges (3 mL), and Vials (10 mL): 100 IU/mL (U-100); Concentrated Prefilled Pen (Toujeo): 300 IU/mL (U-300)
Dosage Forms & Available Strengths:
Prefilled Disposable Pens (SoloStar / KwikPen, 3 mL), Cartridges (3 mL), and Vials (10 mL): 100 IU/mL (U-100); Concentrated Prefilled Pen (Toujeo): 300 IU/mL (U-300)
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Long-Acting (Basal) Recombinant Human Insulin Analogue (Peakless 24-Hour Basal Profile) acting on target receptor/enzyme pathways in Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04): clinical efficacy is mediated via Long-Acting (Basal) Recombinant Human Insulin Analogue (Peakless 24-Hour Basal Profile) for Basal insulin therapy for Type 1 and Type 2 diabetes mellitus (controls fasting and inter-meal hepatic glucose output over 24 hours)..

4. Therapeutic Indications & Evidence-Supported Uses

  • Basal insulin therapy for Type 1 and Type 2 diabetes mellitus (controls fasting and inter-meal hepatic glucose output over 24 hours)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: Administered subcutaneously once daily. In Type 2 DM, typically initiated at 10 IU once daily (or 0.1–0.2 IU/kg/day) and titrated by 2 IU every 3 days until Fasting Blood Glucose reaches target (90–130 mg/dL). Pharmacokinetic Profile: Onset 1.5–2 hours, no pronounced peak, duration 20–24 hours (U-100) or >24–36 hours (U-300). Follow physician prescription.

Administration & Meal Timing: Independent of meals (does not need to be timed with food because it provides steady background basal insulin without a mealtime spike). | Once daily at the exact same clock hour every day (commonly at bedtime [10:00 PM] or morning [08:00 AM]).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Dosing depends on renal clearance! Reduce glargine dose by 20–35% as eGFR declines below 45 and 30 mL/min. Hepatic: Reduce dose in hepatic cirrhosis due to impaired nocturnal gluconeogenesis.
Elimination & Renal Adjustment:
Renal: Dosing depends on renal clearance! Reduce glargine dose by 20–35% as eGFR declines below 45 and 30 mL/min. Hepatic: Reduce dose in hepatic cirrhosis due to impaired nocturnal gluconeogenesis.
Hepatic Impairment Considerations:
Renal: Dosing depends on renal clearance! Reduce glargine dose by 20–35% as eGFR declines below 45 and 30 mL/min. Hepatic: Reduce dose in hepatic cirrhosis due to impaired nocturnal gluconeogenesis.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Crystal-Clear Acidic Solution (pH 4.0): Must NEVER be mixed or diluted with any other insulin (e.g., Regular or Aspart) in the same syringe—mixing alters the acidic pH, causing precipitation and destroying the slow microprecipitate depot! Must NEVER be given intravenously.

Key Clinical Precautions: Renal: Dosing depends on renal clearance! Reduce glargine dose by 20–35% as eGFR declines below 45 and 30 mL/min. Hepatic: Reduce dose in hepatic cirrhosis due to impaired nocturnal gluconeogenesis.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Hypoglycaemia (significantly lower nocturnal hypoglycaemia rate than NPH/Mixtard), injection-site pain/stinging (due to acidic pH 4.0), lipohypertrophy, modest weight gain.
  • Severe hypoglycaemia (especially if accidentally injected intramuscularly into a thin limb or confused with rapid-acting mealtime insulin), hypokalaemia.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Oral antidiabetics, ACE inhibitors, beta-blockers (mask hypoglycaemia tachycardia), fluoroquinolones, and alcohol enhance hypoglycaemia
  • Corticosteroids and thiazides increase basal insulin need

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Explain that Glargine is a 'crystal-clear 24-hour background insulin'—never roll/shake it, never mix it with another insulin in one syringe, and never confuse the Glargine pen with a mealtime rapid-acting pen (use tactile rubber bands or colour markers on the pens!). Do not stop basal insulin completely during sick days even if eating less, though dose adjustment with SMBG is required.
  • Meal & Clock Timing Instruction: Independent of meals (does not need to be timed with food because it provides steady background basal insulin without a mealtime spike). (Once daily at the exact same clock hour every day (commonly at bedtime [10:00 PM] or morning [08:00 AM]).)
  • Missed Dose Protocol: For Glargine U-100: if remembered within a few hours, inject and monitor glucose; if remembered >8–12 hours late, contact the physician (do not inject two full doses within 12 hours). For Toujeo U-300: may be injected up to 3 hours before or after the usual time.
  • Geriatric Dispensing Pearl: Strongly preferred over NPH or premixed 30/70 in elderly CGHS patients because its flat, peakless profile reduces dangerous 02:00–04:00 AM nocturnal hypoglycaemia by >40–50%. Target slightly relaxed fasting glucose (110–150 mg/dL) in frail elderly.

Storage, Stability & Dispensing Safeguards: COLD CHAIN MANDATORY (2°C–8°C): Store in a pharmaceutical refrigerator between 2°C and 8°C; DO NOT FREEZE. Protect from light and heat during dispensing.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 04 [4.14] (p. 51)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.